Travere Therapeutics profit margin TVTX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.

Net margin, 12 months: −7.4%
Operating margin, 12 months: −6.8%
Net margin on a year earlier: +43.3 pts
Peer median: 18.1%

Over the twelve months to Jun 30, 2026, Travere Therapeutics kept −7.4% of its revenue as net profit, with an operating margin of −6.8% and a gross margin of 98.6%.

The median for 10 large drugmakers of a similar size is 18.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	−5.2%	−12.8%	97.9%
FY2024	n/a	n/a	96.7%
FY2023	−76.7%	n/a	92.1%
FY2022	n/a	n/a	n/a
FY2021	−79.2%	−71.1%	97.0%
FY2020	−85.4%	−88.8%	96.9%
FY2019	−83.5%	−78.3%	97.0%
FY2018	−62.5%	−48.7%	96.6%
FY2017	−38.6%	−34.7%	97.7%
FY2016	−35.9%	−43.6%	96.6%
FY2015	n/a	−50.8%	97.8%
FY2014	n/a	n/a	98.0%
FY2013	n/a	n/a	n/a
FY2012	n/a	n/a	n/a
FY2012	n/a	n/a	n/a

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year	Operating margin
Q2 FY26	Jun 30, 2026	−7.4%	+43.3 pts	−6.8%
Q1 FY26	Mar 31, 2026	−4.0%	+78.9 pts	−10.6%
Q4 FY25	Dec 31, 2025	−5.2%	n/a	−12.8%
Q3 FY25	Sep 30, 2025	−20.3%	n/a	−20.9%
Q2 FY25	Jun 30, 2025	−50.6%	+31.5 pts	−51.6%
Q1 FY25	Mar 31, 2025	−82.9%	n/a	−83.1%
Q4 FY24	Dec 31, 2024	n/a	n/a	n/a
Q3 FY24	Sep 30, 2024	n/a	n/a	n/a
Q2 FY24	Jun 30, 2024	−82.1%	n/a	n/a
Q1 FY24	Mar 31, 2024	n/a	n/a	n/a
Q4 FY23	Dec 31, 2023	−76.7%	n/a	n/a
Q3 FY23	Sep 30, 2023	−67.2%	n/a	n/a

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

Company	Profit margin
TVTXTravere Therapeutics	−7.4%
INDVIndivior Pharmaceuticals	26.7%
ARQTArcutis Biotherapeutics	6.1%
LQDALiquidia	30.7%
KNSAKiniksa Pharmaceuticals International	9.6%
LGNDLigand Pharmaceuticals	67.9%
OGNOrganon	3.4%
AMRXAmneal Pharmaceuticals	5.0%
ALKSAlkermes plc.	4.0%
NRIXNurix Therapeutics	42.0%
TGTXTG Therapeutics	55.2%
Peer median	18.1%

Where Travere Therapeutics ranks

#46of 84Large drugmakers with the highest profit margins

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.